HIKAL Hikal Q3 FY26 results (Oct–Dec 2025) and concall
Hikal reported a resilient Q3 FY26 with consolidated revenue of INR494 crores and EBITDA of INR83 crores, marking a positive turning point after navigating regulatory challenges. The Pharmaceutical segment showed strong recovery, though overall pharma growth for FY26 is now expected to be less than double-digit due to FDA-related delays. The Crop Protection segment continued to face margin pressure from overcapacity and pricing, while the company is strategically diversifying into Animal Health and Personal Care, with significant capex investments made in R&D and manufacturing facilities.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 10.4%, net profit down 134.3% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 453 | 448 | 552 | 380 | 319 −30% | 494 +10% |
| EBITDA | 75 | 72 | 123 | 25 | 7 −90% | 83 +15% |
| Net profit | 18 | 17 | 50 | -22 | -35 −291% | -6 −134% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
